UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2015
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35558 |
|
27-2004382 |
(State or other jurisdiction |
|
(Commission File |
|
IRS Employer |
of incorporation or organization) |
|
Number) |
|
Identification No.) |
11055 Flintkote Avenue, Suite A
San Diego, CA 92121
(Address of principal executive offices)
Registrants telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On May 13, 2015, Trovagene, Inc. (the Company) issued a press release announcing that clinical data from four studies utilizing its Precision Cancer MonitoringSM platform will be presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, IL. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 Press Release of Trovagene, Inc. dated May 13, 2015